| Literature DB >> 33481342 |
Shohei Kishimoto1, Hideyuki Sasaki2, Seigo Kurisu1, Kenichi Ogawa3, Shohei Matsuno1, Hiroto Furuta1, Mikio Arita4, Keigo Naka5, Kishio Nanjo5, Takashi Akamizu1.
Abstract
AIMS/Entities:
Keywords: Diabetic polyneuropathy; Extensor digitorum brevis muscle; Practical screening method
Mesh:
Year: 2020 PMID: 33481342 PMCID: PMC7926247 DOI: 10.1111/jdi.13367
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Figure 1(a) The Japanese traditional sitting style, s eiza (kneeling and siting over one’s heels on the floor), is shown. The normal appearance of (b) the extensor digitorum brevis and atrophic (c) extensor digitorum brevis found in a man with a daily s eiza habit or in (d) a male diabetic symmetric polyneuropathy patient are shown.
Demographic, anthropometry, lifestyle, lifestyle‐related diseases and neurological functions data by sex or the extensor digitorum brevis atrophy
| Male | Female | Male vs female | ||||||
|---|---|---|---|---|---|---|---|---|
| EDBA: (+) ( | 162/794 (20%)* | 483/1,099 (44%)* |
| |||||
|
| 459/239/49/39 (59%▲/30%▼/6%▼/5%▼)* | 279/490/209/115 (25%▼/45%▲/19%▲/11%▲)* |
| |||||
| Total, | EDBA (−), | EDBA (+), |
| Total, | EDBA (−), | EDBA (+), |
| |
|
| 61▲/29/5▼/5* | 49▼/34/12▲/5* | 0.0032* | 28△/47/17▽/8▼* | 22▽/42/22△/14▲* | <0.0001* | ||
| Age (years) | 62.5 ± 9.1 | 61.6 ± 9.4* | 66.4 ± 6.6* | <0.0001* | 62.2 ± 9.3 | 60.9 ± 9.6* | 64.0 ± 8.7* | <0.0001* |
| Height (cm) | 167.7 ± 6.3 | 168.1 ± 6.3* | 166.3 ± 6.1* | 0.0012* | 154.7 ± 5.8 | 155.4 ± 5.6* | 153.9 ± 5.8* | <0.0001* |
| Weight (kg) | 65.6 ± 9.7 | 66.1 ± 9.3* | 63.8 ± 10.9* | 0.0070* | 53.3 ± 8.9 | 52.7 ± 8.7* | 54.0 ± 9.0* | 0.0157* |
| Waist circumference (cm) | 86.6 ± 8.6 | 86.9 ± 8.3* | 85.3 ± 9.5* | 0.0331* | 82.7 ± 9.1 | 81.8 ± 9.1* | 83.8 ± 8.9* | 0.0004* |
| Alcohol: no/social/daily (%) | 35/15/50 | 35/14/51 | 38/16/46 | 0.4961 | 68/21/11 | 66/21/13 | 69/21/10 | 0.4359 |
| Smoking: no/current/previously (%) | 15/20/65 | 14/22/64 | 18/16/66 | 0.1560 | 60/3/37 | 58/4/38 | 61/3/36 | 0.5059 |
| Diabetes: normal/preDM/NDM/KDM (%) | 60/24/3/13 | 62▲/24/3/11▼* | 51▼/23/4/22▲* | 0.0015* | 72/19/2/7 | 74/17/3/6 | 70/21/2/7 | 0.3340 |
| Hypertension: ONBP/EBP/HT (%) | 33/15/52 | 35△/16/49▼* | 25▽/12/63▲* | 0.0078* | 48/11/41 | 52▼/10/38▼* | 42▲/12/46▼* | 0.0025* |
| Dyslipidemia ( | 438/793 (55%) | 349/632 (55%) | 89/161 (55%) | 0.9895 | 632/1099 (58%) | 350/616 (57%) | 282/483 (58%) | 0.6020 |
| Bilateral neuropathic symptoms ( | 56/792 (7%) | 36/631 (6%)* | 20/161 (12%)* | 0.0030* | 100/1093 (9%) | 56/614 (9%) | 44/479 (9%) | 0.9704 |
| Diminished ATRs ( | 126/793 (16%) | 86/631 (14%)* | 40/162 (25%)* | 0.0006* | 156/1098 (14%) | 65/615 (11%)* | 91/483 (19%)* | <0.0001* |
| QVT right (dB) | 20.4 ± 7.8 | 19.7 ± 7.9* | 23.0 ± 6.8* | <0.0001* | 18.6 ± 8.3 | 17.7 ± 8.6* | 19.8 ± 7.9* | <0.0001* |
| QVT left (dB) | 20.7 ± 8.1 | 20.0 ± 8.0* | 23.5 ± 7.9* | <0.0001* | 19.0 ± 8.5 | 18.1 ± 8.8* | 20.2 ± 8.0* | <0.0001* |
| Both QVT impairment ( | 41/794 (5%) | 32/632 (5%) | 9/162 (6%) | 0.8006 | 59/1098 (5%) | 36/615 (6%) | 23/483 (5%) | 0.4258 |
| SPN ( | 26/794 (3%) | 8/632 (1%)* | 18/162 (11%)* | <0.0001* | 42/1099 (4%) | 16/616 (3%)* | 26/483 (5%)* | 0.0168* |
| AMP right, μV ( | 15.0 ± 8.1 (253) | 15.6 ± 8.1 (196)* | 13.0 ± 7.8 (57)* | 0.0308* | 14.1 ± 7.3 (362) | 15.2 ± 7.4 (233)* | 12.0 ± 6.8 (129)* | <0.0001* |
| AMP left, μV (v) | 14.3 ± 8.3 (255) | 15.3 ± 8.6 (196) | 11.2 ± 6.3 (59) | 0.0008 | 13.6 ± 6.7 (361) | 14.6 ± 7.0 (232)* | 11.8 ± 5.7 (129)* | 0.0002* |
| Bilateral AMP impairment ( | 16/258 (6%) | 8/197 (4%)* | 8/61 (13%)* | 0.0104* | 16/363 (4%) | 8/232 (3%) | 8/131 (6%) | 0.2360 |
| CV right, m/s ( | 51.9 ± 4.6 (252) | 52.2 ± 4.3 (195) | 51.2 ± 5.2 (57) | 0.1868 | 56.4 ± 4.2 (361) | 56.2 ± 4.3 (233) | 56.8 ± 4.0 (128) | 0.1968 |
| CV left, m/s ( | 51.4 ± 4.4 (254) | 51.7 ± 4.3 (196)* | 50.3 ± 4.5 (58)* | 0.0243* | 55.3 ± 4.3 (357) | 55.4 ± 4.3 (231) | 55.3 ± 4.2 (126) | 0.8626 |
| Bilateral CV impairment ( | 27/257 (11%) | 20/197 (10%) | 7/60 (12%) | 0.7377 | 8/365 (2%) | 7/233 (3%) | 1/132 (1%) | 0.1590 |
Continuous variables are expressed as the mean ± standard deviation, and analyzed by one‐way anova. Nominal variables were analyzed using the χ2‐test. Then the residual analysis was used as a post‐hoc test. ▽ P < 0.05 (decreased), ▼ P < 0.01 (decreased), △ P < 0.05 (increased), ▲ P < 0.01 (increased). *Statistically significant P‐value. AMP, amplitude of sensory nerve action potential; ATR, Achilles tendon reflex; CV, conduction velocity; EBP, elevated blood pressure; EDB, extensor digitorum brevis muscle; EDBA, extensor digitorum brevis muscle atrophy; HT, hypertension; KDM, known diabetes; NDM, newly diagnosed diabetes; ONBP, optimal/normal blood pressure; preDM, prediabetes; QVT, quantitative vibratory perception threshold; SPN, symmetric polyneuropathy.
Factors associated with extensor digitorum brevis atrophy analyzed by multivariate logistic regression analysis in total participants or in participants without daily and previous seiza habit
| Total participants | Participants without daily and previous ‘Seiza’ habit | |||||||
|---|---|---|---|---|---|---|---|---|
| Male | Female | Male vs female | Male | Female | Male vs female | |||
| Prevalence of EDBA ( | 162/794 (20%)* | 483/1099 (44%)* |
| 133/698 (19%)* | 302/766 (39%)* |
| ||
| Dependent variable | EDBA (+) | EDBA (+) | EDBA (+) | EDBA (+) | ||||
|
|
|
|
| |||||
| Independent variables | OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
|
| Age (years) | 1.073 (1.039–0.108)* | <0.0001* | 1.037 (1.018–1.056)* | <0.0001* | 1.063 (1.028–1.099)* | 0.0003* | 1.045 (1.023–1.067)* | <0.0001* |
| Height (cm) | 0.977 (0.938–1.017) | 0.2540 | 0.950 (0.923–0.979)* | 0.0006* | 0.967 (0.926–1.010) | 0.1299 | 0.953 (0.920–0.988)* | 0.0081* |
| Weight (kg) | 1.048 (0.994–1.105) | 0.0831 | 1.061 (1.026–1.097)* | 0.0005* | 1.058 (1.000–1.119) | 0.0509 | 1.063 (1.022–1.106)* | 0.0024* |
| Waist circumference (cm) | 0.946 (0.898–0.997)* | 0.0393* | 0.974 (0.944–1.004) | 0.0903 | 0.944 (0.893–0.991)* | 0.0421* | 0.965 (0.930–1.002) | 0.0602 |
|
| 1.323 (0.868–2.016) | 0.1928 | 1.293 (0.937–1.785) | 0.1180 | ||||
| vs daily | 2.762 (1.369–5.571)* | 0.0045* | 1.818 (1.238–2.671)* | 0.0023* | ||||
| vs previous | 0.985 (0.417–2.326) | 0.9725 | 2.134 (1.338–3.404)* | 0.0015* | ||||
| Alcohol, no vs social | 0.857 (0.471–1.560) | 0.6143 | 1.020 (0.741–1.402) | 0.9053 | 1.103 (0.586–2.076) | 0.7622 | 0.938 (0.642–1.371) | 0.7404 |
| vs daily | 0.833 (0.542–1.279) | 0.4032 | 0.883 (0.581–1.342) | 0.5602 | 0.996 (0.625–1.586) | 0.9849 | 0.877 (0.534–1.439) | 0.6031 |
| Smoking, no vs current | 0.611 (0.312–1.196) | 0.1506 | 0.756 (0.355–1.607) | 0.4669 | 0.623 (0.313–1.242) | 0.1787 | 0.779 (0.310–1.953) | 0.5939 |
| vs previous | 0.717 (0.429–1.198) | 0.2038 | 0.857 (0.657–1.119) | 0.2575 | 0.581 (0.340–0.993)* | 0.0469* | 0.878 (0.637–1.212) | 0.4294 |
| Diabetes, normal vs preDM | 1.039 (0.650–1.662) | 0.8716 | 1.022 (0.731–1.431) | 0.8975 | 1.036 (0.624–1.720) | 0.8912 | 0.995 (0.658–1.503) | 0.9796 |
| vs NDM | 2.582 (0.956–6.973) | 0.0613 | 0.498 (0.210–1.183) | 0.1142 | 2.213 (0.788–6.220) | 0.1318 | 0.306 (0.077–1.220) | 0.0934 |
| vs KDM | 1.77 (1.028–3.05)* | 0.0396* | 0.81 (0.481–1.381) | 0.4479 | 1.92 (1.094–3.394)* | 0.0231* | 1.15 (0.603–2.198) | 0.6698 |
| Hypertension, ONBP vs EBP | 0.78 (0.410–1.514) | 0.4749 | 1.20 (0.789–1.846) | 0.3866 | 0.79 (0.388–1.614) | 0.5196 | 1.12 (0.655–1.913) | 0.6790 |
| vs HT | 1.27 (0.795–2.041) | 0.3134 | 1.06 (0782–1.450) | 0.6881 | 1.4 (0.841–2.348) | 0.1941 | 1.01 (0.700–1.462) | 0.9504 |
| Dyslipidemia, NL vs DL | 1. (0.670–1.493) | 0.9989 | 0.82 (0.625–1.082) | 0.1615 | 1.06 (0.692–1.648) | 0.7677 | 0.72 (0.519–1.012) | 0.0590 |
| SPN | 7.38 (2.957–18.454)* | <0.0001* | 2.39 (1.181–4.848)* | 0.0155* | 6.85 (2.632–17.854)* | <0.0001* | 1.47 (0.622–3.491) | 0.3790 |
Statistical analyses were carried out by multivariate logistic regression analysis. *Statistically significant values. CI, confidence interval; DL, dyslipidemia; DM, diabetes mellitus; EBP, elevated blood pressure; EDBA, extensor digitorum brevis muscle atrophy; HT, hypertension; KDM, known diabetes; NDM, newly diagnosed diabetes; NL, normolipidemia; ONBP, optimal/normal blood pressure; OR, odds ratio; preDM, prediabetes; SPN, symmetric polyneuropathy.
Relationships between neurological functions and extensor digitorum brevis muscle atrophy in the participants without daily and previous seiza habit by sex or the presence of diabetes
| (a) | Participants with diabetes | Participants without diabetes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Male vs female | Male | Female | Male vs female | |||||||
| Prevalence of EDBA (+) ( | 38/117 (32%) | 26/58 (45%) |
| 95/581 (16%) | * | 276/708 (39%)* |
| |||||
| Prevalence of SPN/DSPN ( | 9/117 (8%) | 4/58 (7%) |
| 13/581 (2%) | 21/708 (3%) |
| ||||||
| EDBA (–) | EDBA (+) |
| EDBA (–) | EDBA (+) |
| EDBA (–) | EDBA (+) |
| EDBA (–) | EDBA (+) |
| |
| AMP right, μV ( | 13.5 ± 4.9 (23)* | 8.9 ± 6.7 (15)* | 0.02 | 13.1 ± 7.7 (16) | 13.0 ± 6.5 (8) | 0.9689 | 16.4 ± 8. (150) | 15.3 ± 7.8 (35) | 0.5 | 15.8 ± 7. (168)* | 12.6 ± 7.7 (76)* | 0.0017* |
| AMP left, μV ( | 13.3 ± 5.7 (23)* | 8.1 ± 5.7 (17)* | 0.0075* | 13.0 ± 7.6 (15) | 12.9 ± 5.2 (8) | 0.9675 | 16.0 ± 8. (151) | 12.9 ± 6.4 (35) | 0.0509 | 14.8 ± 6.9 (168)* | 12.1 ± 6.1 (77)* | 0.0027* |
| AMP impairment ( | 2/23 (9%) | 5/17 (29%) | 0.0883 | 2/16 (13%) | 1/8 (13%) | – | 3/151 (2%) | 3/37 (8%) | 0.0576 | 3/167 (2%)* | 6/77 (8%)* | 0.0209* |
| CV right, m/s ( | 51.7 ± 4. (23) | 48.1 ± 6. (15) | 0.0520 | 55.8 ± 4. (16) | 57.4 ± 3. (8) | 0.3535 | 52.3 ± 4. (149) | 52.8 ± 3. (35) | 0.5133 | 56.4 ± 4. (168) | 57.1 ± 4. (76) | 0.2613 |
| CV left, m/s ( | 50.5 ± 3.9 (23)* | 47.1 ± 4. (16)* | 0.0214* | 53.4 ± 5.9 (15) | 53.5 ± 4. (8) | 0.9678 | 52.0 ± 4. (151) | 51.7 ± 3. (35) | 0.7265 | 55.5 ± 4.3 (167) | 55.8 ± 4.1 (74) | 0.6198 |
| CV decline ( | 3/23 (13%) | 6/17 (35%) | 0.0957 | 1/16 (6%) | 0/8 (0%) | 0.4701 | 14/151 (9%) | 0/36 (0%) | 0.0575 | 6/168 (4%) | 0 /78 (0%) | 0.0911 |
| QVT right (dB) | 21.2 ± 7.6* | 24.0 ± 6.4* | 0.0492* | 19.4 ± 8.3* | 24.1 ± 6.2* | 0.0182* | 19.4 ± 8.0* | 22.1 ± 7.3* | 0.0023* | 16.9 ± 8.5* | 18.8 ± 8.4* | 0.0038* |
| QVT left (dB) | 21.9 ± 7.6* | 25.9 ± 6.6* | 0.0074* | 19.5 ± 7.8* | 23.4 ± 4.4* | 0.0291* | 19.5 ± 8.0* | 22.0 ± 8.5* | 0.0069* | 17.4 ± 8.8* | 19.1 ± 8.4* | 0.0121* |
| QVT impairment ( | 3/78 (4%) | 3/38 (8%) | 0.3467 | 1/32 (3%) | 0/26 (0%) | 0.3632 | 25/486 (5%) | 5/95 (5%) | 0.9617 | 26/431 (6%) | 12/276 (4%) | 0.3326 |
| Symptoms ( | 7/79 (9%) | 8/38 (21%) | 0.065 | 6/32 (19%) | 5/25 (20%) | 0.9055 | 25/486 (5%) | 7/95 (7%) | 0.3847 | 42/432 (10%) | 23/276 (8%) | 0.5325 |
| Reduced ATRs: ( | 18/79 (23%) | 15/38 (39%) | 0.0603 | 4/32 (13%) | 7/26 (27%) | 0.1635 | 61/485 (13%) | 18/95 (19%) | 0.0979 | 38/432 (9%)* | 50/276 (18%)* | 0.0002* |
| DSPN/SPN ( | 1/79 (1%)* | 8/38 (21%)* | 2E‐04* | 2/32 (6%) | 2/26 (8%) | 0.8293 | 7/486 (1%)* | 6/95 (6%)* | 0.003* | 10/432 (2%) | 11/276 (4%) | 0.2013 |
(a) Data of quantitative nerve functions tests, prevalence of impairment in each test and symmetric polyneuropathy (SPN)/diabetic symmetric polyneuropathy (DSPN) diagnosed by “Probable DSPN” criteria of the Toronto Consensus. (b) Sensitivity, specificity, positive and negative predictive values and reliability of extensor digitorum brevis muscle atrophy (EDBA) detection in diagnosing DSPN/SPN. Continuous variables were expressed as the mean ± standard deviation, and analyzed by one‐way anova. Nominal variables were analyzed by the χ2‐test and Cohen’s kappa coefficient method. The participants with daily or previous seiza habit were excluded. *Statistically significant values. AMP, nerve action potential amplitude of the sural nerve; ATR, Achilles tendon reflex; CV, conduction velocity of the sural nerve; n, number; QVT, quantitative vibratory perception threshold.
Figure 2Female sex, high body mass index (BMI) and diabetic symmetric polyneuropathy (DSPN )were significantly associated with extensor digitorum brevis atrophy (EDBA) in Japanese established diabetes patients by multiple logistic regression analysis. DL, dyslipidemia; HT, hypertension. OR, odds ratio.
Associated factors with extensor digitorum brevis muscle atrophy and the validity of extensor digitorum brevis muscle atrophy detection to diagnose diabetic symmetric polyneuropathy
| (a) | Male ( | Female ( | Male vs female | |||
|---|---|---|---|---|---|---|
| Prevalence of EDBA (n) | 21/79 (27%)* | 26/54 (48%)* | P = 0.0106* | |||
| Prevalence of DSPN ( | 34/79 (43%)* | 12/54 (22%)* |
| |||
| EDBA (–) | EDBA (+) |
| EDBA (–) | EDBA (+) |
| |
|
| 58 | 21 | 28* | 26* | ||
| Age (years) | 56.4 ± 9.7* | 61.9 ± 9.2* | 0.0293* | 59.2 ± 11.0 | 62.7 ± 11.4 | 0.2539 |
| Duration of diabetes (year) | 12.8 ± 9.1* | 20.9 ± 13.9* | 0.0049* | 15.2 ± 16.1 | 16.1 ± 11.0 | 0.7800 |
| Height (cm) | 168.1 ± 5.6 | 166.5 ± 5.7 | 0.2624 | 156.0 ± 4.9 | 154.1 ± 8.1 | 0.3358 |
| Weight (kg) | 73.8 ± 13.7* | 64.0 ± 14.3* | 0.0077* | 63.7 ± 13.9 | 58.3 ± 13.2 | 0.1654 |
| Body mass index (kg/m2) | 26.0 ± 4.1* | 23.0 ± 4.6* | 0.0078* | 26.2 ± 5.3 | 24.5 ± 4.8 | 0.2438 |
| Alcohol: daily ( | 23/53 (43%) | 7/21 (33%) | 0.4269 | 1/24 (4%) | 4/24 (17%) | 0.1563 |
| Smoking: current or previous ( | 33/54 (61%) | 12/21 (57%) | 0.7528 | 4/24 (17%) | 2/24 (8%) | 0.3827 |
| HbA1c (%) | 8.9 ± 2.1 | 8.9 ± 2.7 | 0.9732 | 8.9 ± 1.9 | 8.2 ± 2.0 | 0.2821 |
| Hypertension ( | 27/54 (50%) | 12/21 (57%) | 0.5728 | 11/24 (46%) | 14/24 (58%) | 0.3861 |
| Dyslipidemia ( | 28/54 (52%) | 10/21 (48%) | 0.7420 | 15/24 (63%) | 16/24 (67%) | 0.7628 |
| Retinopathy: NDR/SDR/PPDR< (%) | 61/14/25 | 40/10/50 | 0.1387 | 76/14/10 | 50/21/29 | 0.1600 |
| Proteinuria: no/micro/macro (%) | 66/17/17 | 76/5/19 | 0.3957 | 83/4/13 | 75/17/8 | 0.3490 |
| Autonomic nerve functions | ||||||
| CV rest impairment ( | 18/56 (32%)* | 12/19 (63%)* | 0.0171* | 6/27 (22%)* | 16/26 (62%)* | 0.0037* |
| CV deep impairment ( | 20/56 (36%) | 10/19 (53%) | 0.1934 | 7/27 (26%) | 11/26 (42%) | 0.2081 |
| Orthostatic hypotension ( | 7/58 (12%)* | 10/20 (50%)* | 0.0004* | 2/28 (7%) | 4/26 (15%) | 0.3356 |
| Nerve conduction parameters | ||||||
| Ulnar MCV impairment ( | 11/36 (31%) | 6/11 (55%) | 0.1473 | 1/12 (8%) | 3/8 (37%) | 0.1101 |
| Ulnar CMAP impairment ( | 2/35 (6%) | 1/11 (9%) | 0.6924 | IC | IC | IC |
| Median SCV impairment ( | 20/34 (58%)* | 11/11 (100%)* | 0.0103* | 1/12 (8%) | 2/7 (28) | 0.2432 |
| Median SNAP impairment ( | 8/33 (24%) | 5/11 (45%) | 0.1817 | 0/12 (0%) | 1/7 (14%) | 0.1786 |
| Tibial MCV impairment ( | 18/34 (53%)* | 10/11 (91%)* | 0.0240* | 3/13 (23%)* | 6/7 (85%)* | 0.0072* |
| Tibial CMAP impairment ( | 10/34 (29%)* | 8/11 (73%)* | 0.0108* | 3/13 (23%) | 2/7 (29%) | 0.7866 |
| QVT impairment ( | 6/58 (10%)* | 10/21 (48%)* | 0.0003* | 1/28 (4%) | 5/26 (19%) | 0.0673 |
| Neuropathic symptoms ( | 21/58 (36%)* | 14/21 (67%)* | 0.0161* | 6/28 (21%) | 10/26 (38%) | 0.1708 |
| Reduced ATRs: ( | 25/58 (43%)* | 17/21 (81%)* | 0.0029* | 12/28 (43%) | 12/26 (46%) | 0.8075 |
| DSPN ( | 19/58 (33%)* | 15/21 (71%)* | 0.0022* | 6/28 (21%) | 6/26 (23%) | 0.8843 |
(a) Relationships between clinical factors, neurological dysfunctions and EDBA in diabetic patients by gender. (b) Sensitivity, specificity, positive and negative predictive values, and reliability of extensor digitorum brevis muscle atrophy (EDBA) to diagnose diabetic symmetric polyneuropathy (DSPN) in established diabetic patients. Continuous variables were expressed as mean ± standard deviation, and analyzed by one‐way anova. Nominal variables were analyzed by the χ2‐test and Cohen’s kappa coefficient methods. *Statistically significant values. ATR, Achilles tendon reflex; CMAP, compound muscle action potential; CV, coefficient of variation in R‐R interval of electrocardiogram; EDB, extensor digitorum brevis muscle; IC, incalculable; Macro, macroalbuminuria; MCV, motor nerve conduction velocity; Micro, microalbuminuria; n, number; NDR, no diabetic retinopathy; No, no‐albuminuria; P/N, positive/negative; PPDR<, proproliferative diabetic retinopathy or more; QVT, quantitative vibratory perception threshold; SCV, sensory nerve conduction velocity; SDR, simple diabetic retinopathy; SNAP, sensory nerve action potential.